Endocrinology & Metabolism Clinical Trials

Statistical methods in endocrinology & metabolism trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All endocrinology & metabolism trials

909 results

• BEGIN™Independent statistical analysis of Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 460NCT01068678
• BEGIN™Independent statistical analysis of Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01079234).Phase 3Results postedn = 493NCT01079234
• Beige Fat, Energy, and the Natriuretic Peptide System: Complete Statistical AnalysisIndependent statistical analysis of Beige Fat, Energy, and the Natriuretic Peptide System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04357964).Phase NAResults postedn = 137NCT04357964
• Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin: Complete Statistical AnalysisIndependent statistical analysis of Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin:…Phase 2Results postedn = 29NCT00993616
• BETonMACEComplete statistical analysis of the BETonMACE phase 3 trial of apabetalone versus placebo in high-risk patients with type 2 diabetes and coronary artery disease, including time-to-event methodology, hazard ratios, confidence intervals, p-values,…Phase 3Results postedn = 2,425NCT02586155
• BevacizumabIndependent statistical analysis of A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 121NCT00336323
• Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection: Complete Statistical AnalysisIndependent statistical analysis of Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03167411).Phase 1Results postedn = 20NCT03167411
• BI 10773 add-on to Metformin in Patients With Type 2 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of BI 10773 add-on to Metformin in Patients With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 495NCT00749190
• BingocizeIndependent statistical analysis of Bingocize: A Novel Mobile Application for Older Adult Health: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03629912).Phase NAResults postedn = 241NCT03629912
• Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation: Complete Statistical AnalysisIndependent statistical analysis of Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 6NCT04390243
• Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A): Complete Statistical AnalysisIndependent statistical analysis of Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1Results postedn = 24NCT00899470
• Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia: Complete Statistical AnalysisIndependent statistical analysis of Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 81NCT02409459
• BLIR-HIVIndependent statistical analysis of Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01228318).Phase 2Results postedn = 63NCT01228318
• Blueberry Consumption and Type 2 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Blueberry Consumption and Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02972996).Phase NAResults postedn = 55NCT02972996
• Body Weight, Sleep, and Heart Health: Complete Statistical AnalysisIndependent statistical analysis of Body Weight, Sleep, and Heart Health: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03388788).Phase NAResults postedn = 17NCT03388788
• BODY-REALIndependent statistical analysis of Clinical Effectiveness of Body Fat Distribution Imaging in Real-World Practice: The BODY-REAL Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 29NCT04763772
• BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.: Complete Statistical AnalysisIndependent statistical analysis of BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 677NCT00545779
• BOOST™Independent statistical analysis of Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 548NCT00978627
• Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis:…Phase NAResults postedn = 20NCT01383759
• BROADWAYA detailed statistical analysis of the phase 3 BROADWAY trial evaluating obicetrapib on top of maximum tolerated lipid-modifying therapies in patients with dyslipidemias and high cardiovascular risk.Phase 3Results postedn = 2,530NCT05142722
• BROOKLYNIndependent statistical analysis of Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 354NCT05425745
• BSSIndependent statistical analysis of Blue Sky Study: Impact of Milk and Vitamin D for Child Growth and Health: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 597NCT00886379
• BULLETIndependent statistical analysis of BULLET: Bladder Ultrasound Limits Length (of Time), Expedites Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03860311).Phase NAResults postedn = 45NCT03860311
• Buoy Electrolyte Study on Hydration Status of Active Men and Women: Complete Statistical AnalysisIndependent statistical analysis of Buoy Electrolyte Study on Hydration Status of Active Men and Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 30NCT05768789
• Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 230NCT03180294
• Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 102NCT01935934
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors: Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 109NCT02867592
• CACD1Independent statistical analysis of Cardiovascular Risk Stratification in Young People With Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05283538).Phase NAResults postedn = 91NCT05283538
• Calcium Absorption in Patients With Rothmund-Thomson Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Calcium Absorption in Patients With Rothmund-Thomson Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01304407).Phase NAResults postedn = 29NCT01304407
• CALERIEIndependent statistical analysis of CALERIE (NCT00943215), including trial design, endpoints, planned analyses, statistical methodology, and interpretation of calorie restriction research.n = 42NCT00943215
• CALORIESAn independent statistical analysis and educational interpretation of CALORIES (NCT03961061), a randomized parallel-group trial comparing Brenner mFIT standard care with standard care plus mobile health components in youth.Phase NAResults postedn = 28NCT03961061
• CAP-CholIndependent statistical analysis of Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients: primary endpoint results,…Phase 4Results postedn = 668NCT00631189
• CAPEIndependent statistical analysis of Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05512962).Phase 2Results postedn = 25NCT05512962
• Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment: Complete Statistical AnalysisIndependent statistical analysis of Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00447694).Phase 2Results postedn = 30NCT00447694
• Cardiovascular Outcomes in Bariatric Surgery Patients With Type 2 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Cardiovascular Outcomes in Bariatric Surgery Patients With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03955952).Phase NAResults postedn = 91,700NCT03955952
• Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network: Complete Statistical AnalysisIndependent statistical analysis of Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 1,147NCT01586871
• CATALYSTIndependent statistical analysis of A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1/2Results postedn = 10NCT02545907
• CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas: Complete Statistical AnalysisIndependent statistical analysis of CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00540579).Phase 1/2Results postedn = 23NCT00540579
• CECSIDIndependent statistical analysis of Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 4Results postedn = 59NCT00692237
• CENTAURIndependent statistical analysis of Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 25NCT00728910
• Cerebrotendinous Xanthomatosis (CTX) Prevalence Study: Complete Statistical AnalysisIndependent statistical analysis of Cerebrotendinous Xanthomatosis (CTX) Prevalence Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02638220).Phase NAResults postedn = 442NCT02638220
• CGDNIndependent statistical analysis of N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01265563).Phase 2Results postedn = 108NCT01265563
• Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir: Complete Statistical AnalysisIndependent statistical analysis of Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 11NCT02097108
• Changing Lifestyles for Better Health: Complete Statistical AnalysisIndependent statistical analysis of Changing Lifestyles for Better Health: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00848757).Phase NAResults postedn = 130NCT00848757
• Characterization of Transient Alterations of Cutaneous Sensory Nerve Function by Cryolipolysis: Complete Statistical AnalysisIndependent statistical analysis of Characterization of Transient Alterations of Cutaneous Sensory Nerve Function by Cryolipolysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 11NCT01673113
• Check It! Positive Psychology Intervention to Improve Adherence in Adolescents With T1D: Complete Statistical AnalysisIndependent statistical analysis of Check It! Positive Psychology Intervention to Improve Adherence in Adolescents With T1D: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 120NCT02746627
• Chemoradiation in Locally Advanced Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemoradiation in Locally Advanced Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00262951).Phase 2Results postedn = 23NCT00262951
• Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 11NCT01959672
• CHLIndependent statistical analysis of Children's Healthy Living Community Randomized Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01881373).Phase NAResults postedn = 9,840NCT01881373
• CHOOSEIndependent statistical analysis of Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 3Results postedn = 120NCT01112865

← All therapeutic areas